Literature DB >> 32203185

Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing.

Shao-An Xue1,2, Yuan Chen3,4, Ralf-Holger Voss5, Virad Kisan4, Bo Wang3, Ke-Ke Chen3, Feng-Qin He3, Xiao-Xia Cheng3, Laura Scolamiero4, Angelika Holler4, Liquan Gao4, Emma Morris4, Hans J Stauss6.   

Abstract

Year:  2020        PMID： 32203185      PMCID： PMC7784858          DOI： 10.1038/s41423-020-0396-9

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  4 in total

1.  Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.

Authors:  Sameer Quazi
Journal:  Mol Biol Rep       Date:  2022-02-05       Impact factor: 2.742

2.  Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information.

Authors:  James M Heather; Matthew J Spindler; Marta Herrero Alonso; Yifang Ivana Shui; David G Millar; David S Johnson; Mark Cobbold; Aaron N Hata
Journal:  Nucleic Acids Res       Date:  2022-07-08       Impact factor: 19.160

Review 3.  Emerging Strategies in TCR-Engineered T Cells.

Authors:  Fang Wei; Xiao-Xia Cheng; John Zhao Xue; Shao-An Xue
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

Review 4.  CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.

Authors:  Xuejin Ou; Qizhi Ma; Wei Yin; Xuelei Ma; Zhiyao He
Journal:  Front Cell Dev Biol       Date:  2021-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.